Vigamox

ApprovedSmall molecule

Merck & Co.

Vigamox is one of 44 small molecule programs targeting Bacterial Conjunctivitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial ConjunctivitisActive, not recruiting

CataractActive, not recruiting

Bacterial ConjunctivitisApproved

Active, not recruiting

CataractApproved

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Kenalog

BBausch Health Americas, Inc.

Phase 3

4 2

Floxin

WWim Janssens

Phase 3

1 3

Vigamox

Merck & Co.

Approved

1 4

Phenylephrine Hcl

Bayer

Phase 3

1 5

Zolymbus

AbbVie

Preclinical

—6

Neurontin

VViatris Specialty LLC

Preclinical

3 7

Kenalog

BBassett Healthcare

Preclinical

1 8

Duragesic

CCephalon

Preclinical

1 9

Bactroban

PPadagis LLC

Preclinical

1 10

Ceftin

PPhiladelphia Eye Associates

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bacterial Conjunctivitis3 trials

Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)

Completed·LLaboratorios Sophia S.A de C.V.·Phase 2·NCT02980523·150 enrolled

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora

Completed·AAlcon Research·Phase 4·NCT00312338·137 enrolled

Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment

Completed·AAlcon Research·Phase 4·NCT00798577·24 enrolled

Intravitreal Injections1 trial

Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections

Completed·IIllinois Retina Associates·Phase 4·NCT00690313·22 enrolled

Graft Versus Host Disease1 trial

Vigamox Treatment for Ocular Graft-Versus-Host Disease

Withdrawn·WWashington University School of Medicine·Phase 2·NCT04204122

Cataract1 trial

2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery

Completed·OOphthalmology Consultants, Ltd.·Phase 4·NCT01455233·60 enrolled

Unspecified1 trial

Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00575367·37 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Vigamox. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vigamox compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vigamox. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

Vigamox

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bacterial Conjunctivitis3 trials

Intravitreal Injections1 trial

Graft Versus Host Disease1 trial

Cataract1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News